A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
RADIATION

Radiotherapy

Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.

DRUG

Olaparib Oral Tablet [Lynparza]

Oral tablet

DRUG

AZD1390

Oral tablet

DRUG

Ceralasertib

Oral Tablet

DRUG

AZD5305

Oral Tablet

DRUG

Durvalumab

1500mg iv infusion

Trial Locations (11)

Unknown

RECRUITING

Belfast City Hospital, Belfast

RECRUITING

Addenbrooke's Hospital, Cambridge

RECRUITING

Velindre Cancer Centre, Cardiff

RECRUITING

The Royal Marsden Hospital Chelsea, Chelsea

RECRUITING

Western General Hospital, Edinburgh

RECRUITING

St James's University Hospital, Leeds

RECRUITING

University College Hospital London, London

RECRUITING

The Christie NHS Foundation Trust, Manchester

RECRUITING

Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne

RECRUITING

Weston Park Hospital, Sheffield

RECRUITING

The Royal Marsden Sutton, Sutton

All Listed Sponsors
collaborator

University of Manchester

OTHER

collaborator

Newcastle University

OTHER

collaborator

University of Oxford

OTHER

collaborator

The Leeds Teaching Hospitals NHS Trust

OTHER

collaborator

Beatson West of Scotland Cancer Centre

UNKNOWN

collaborator

University of Glasgow

OTHER

collaborator

Velindre NHS Trust

OTHER_GOV

collaborator

University College London Hospitals

OTHER

collaborator

Queen's University, Belfast

OTHER

collaborator

University of Sheffield

OTHER

lead

University of Leeds

OTHER